Use of pimobendan in 170 cats (2006–2010)

MacGregor, John; Laste, Nancy J.; Malakoff, Rebecca L.; Cunningham, Suzanne M.; Aronow, Natalie; Hall, Daniel J.; Williams, Justin; Price, Lori Lyn

doi:10.1016/j.jvc.2011.08.001

Cited by 40 publications

(46 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Median survival time for cats with CHF in the current study is similar to that reported in previous studies, which ranges from 41 to 626 days 35, 36, 37, 38, 39, 40, 41, 42, 43. There were no associations between medications (including pimobendan) and survival time in the current study, which is likely due to the relatively small sample size and the fact that cats were receiving multiple medications.…”

Section: Discussionsupporting

confidence: 88%

Association between Survival Time and Changes inNT‐proBNPin Cats Treated for Congestive Heart Failure

Pierce

Freeman

Cunningham

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundReductions in N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations after treatment have been associated with improved survival in people with congestive heart failure (CHF), but have not been reported in cats with CHF.ObjectivesTo evaluate changes in NT‐proBNP concentrations in cats with CHF after treatment and determine whether serial NT‐proBNP measurements provide prognostic information.AnimalsThirty‐one client‐owned cats.MethodsProspective, observational study in cats with new onset CHF secondary to cardiomyopathy. Concentrations of NT‐proBNP were measured within 4 hours of admission to the hospital, on the day of discharge, and at re‐evaluation 7–10 days later.ResultsMedian NT‐proBNP concentrations decreased significantly from admission (1,713 pmol/L [range, 160–3,784 pmol/L]) to discharge (902 pmol/L [range, 147–3,223 pmol/L]); P = .005) and from admission to re‐evaluation (1,124 pmol/L [range, 111–2,727 pmol/L]; P = .024). Median survival time was 109 days (range, 1–709 days), with 5 cats still alive at the time of analysis. Cats with a larger percent decrease in NT‐proBNP from admission to discharge had a longer survival time (P = .048). Cats with evidence of active CHF at the time of re‐evaluation (P = .010) and cats whose owners had difficulty administering medications (P = .045) had shorter survival times.Conclusions and clinical importanceCats with a larger percent decrease in NT‐proBNP during hospitalization and no evidence of CHF at the time of re‐evaluation had longer survival times. Additional studies are needed to determine whether NT‐proBNP can help guide treatment in cats with CHF.

show abstract

Section: Discussionsupporting

confidence: 88%

Association between Survival Time and Changes inNT‐proBNPin Cats Treated for Congestive Heart Failure

Pierce

Freeman

Cunningham

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…These observations corroborate the report that pimobendan administered orally at this dose to cats with naturally occurring cardiac disease was well tolerated. 7 It is unknown whether the death of 1 cat, 10 days following completion of the pilot study, was related to the single dose of pimobendan or the cat's involvement in the study. Under close observation, the cat was apparently healthy until the day of death.…”

Section: Discussionmentioning

confidence: 99%

“…In a group of 170 cats with naturally occurring cardiac disease in which pimobendan was administered, the median age was 11 years and most cats received other medications. 7 It is possible that due to cardiac disease, age, concurrent treatment(s), or other comorbidity(s), the bioavailability, metabolism, or excretion of pimobendan and/or desmethylpimobendan could be drastically altered. Even in the absence of clinical signs or physical examination findings of disease, cardiac or other body system disease cannot be completely ruled out in the cats used in this study.…”

Section: Discussionmentioning

confidence: 99%

“…A dose similar to that recommended for dogs (0.25 mg/kg PO q 12 h) has been reported to be safe and well tolerated in cats with naturally occurring cardiac disease. 7 In 170 cats in which pimobendan was administered, hypertrophic cardiomyopathy, DCM, and unrestricted cardiomyopathy were the most common diagnoses. 7 In general, the use of pimobendan in cats with outflow tract obstruction was avoided.…”

Section: Introductionmentioning

confidence: 99%

“…7 In 170 cats in which pimobendan was administered, hypertrophic cardiomyopathy, DCM, and unrestricted cardiomyopathy were the most common diagnoses. 7 In general, the use of pimobendan in cats with outflow tract obstruction was avoided. There have been no studies investigating the pharmacokinetic (PK) properties of pimobendan in cats.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations